Supplementary Figures 1-9 from JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non–small Cell Lung Cancers

Supplemental Figure S1. Comparison of clonogenic survival fractions of various cancer cell lines after treatment with SAR302503 and Ruxolitinib. Supplemental Figure S2. KRAS mutation by treatment sensitivities in NSCLC cell lines. Supplementary Figure S3. The response of NCIH1944 xenografts to ionizing radiation. Supplemental Figure S4. Top-ranked pathways in SAR sensitive NSCLC cell lines. Supplemental Figure S5. Cancer growth and proliferation gene network in SAR-sensitive NSCLC. Supplemental Figure S6. ROC analysis of SAR sensitivity by TSP-IRDS scores. Supplemental Figure S7. Distribution of TSP-IRDS scores in clinical NSCLCs. Supplemental Figure S8. TSP-IRDS predicts survival in clinical NSCLC. Supplemental Figure S9. TSP-IRDS scores predict the benefit of adjuvant cisplatin-based chemotherapy in clinical NSCLC. Supplementary Figure and Table Legends